To include your compound in the COVID-19 Resource Center, submit it here.

Novartis, Pear collaborate on digital therapeutics

Pear Therapeutics Inc. (Boston, Mass.) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to develop Pear's THRIVE technology as a prescription digital

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE